Silver Book Fact

Cost-savings associated with Warfarin use in AFib patients

Warfarin use in Medicare patients with nonvalvular atrial fibrillation was independently associated with lower medical costs averaging $9,836 per patient, per year.

Mercaldi C, Ciaramentaro M, Hahn B, Chalissery G. Cost Efficiency of Anticoagulation with Warfarin to Prevent Stroke in Medicare Beneficiaries with Nonvalvular Atrial Fibrillation. Stroke. 2011; 42(1): 112-8. http://stroke.ahajournals.org/cgi/content/short/42/1/112

Reference

Title
Cost Efficiency of Anticoagulation with Warfarin to Prevent Stroke in Medicare Beneficiaries with Nonvalvular Atrial Fibrillation
Publication
Stroke
Publication Date
2011
Authors
Mercaldi C, Ciaramentaro M, Hahn B, Chalissery G
Volume & Issue
Volume 42, Issue 1
Pages
112-8
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Cost-savings associated with Warfarin use in AFib patients
    Warfarin use in Medicare patients with nonvalvular atrial fibrillation was independently associated with lower medical costs averaging $9,836 per patient, per year.  
  • t-PA cost savings
    The total annual benefit to society from t-PA use in the United States is around $363 million—$60 million in direct cost savings to society plus an additional 7,510 QALYs. This means…  
  • Stroke risk reduction from thrombin inhibitor in AFib patients
    A recently approved direct thrombin inhibitor was found to reduce the risk of stroke/peripheral embolic events in atrial fibrillation patients by 34%, and the risk of hemorrhagic stroke by 74%—compared…  
  • Adjusted-dose warfarin reduced stroke risk in AFib patients
    Meta-analysis of randomized trials found that adjusted-dose warfarin reduced stroke risk in atrial fibrillation patients by 60%. Antiplatelet agents reduced risk by 20%.  
  • Effectiveness of pacemaker/defibrillators to control AFib
    Widespread use of pacemaker/defibrillators to control atrial fibrillation could result in a 50% decrease in stroke.